$CBIS Some of the more noteworthy transactions are with unique strategic partners who already have DEA and Department of Agriculture licenses. This will help ensure a quick and risk-averse path to production and thus the ability to increase its drug output for those patients looking for pharmaceutical grade cannabinoid formulations. This upcoming vote is of the utmost importance to any company serving the cannabis industry, and Cannabis Science is continuing to position itself to serve these new markets pending positive voting results.

http://www.marketwired.com/press-release/prop...171175.htm